184 related articles for article (PubMed ID: 29789356)
1. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.
Testi AM; Pession A; Diverio D; Grimwade D; Gibson B; de Azevedo AC; Moran L; Leverger G; Elitzur S; Hasle H; van der Werff ten Bosch J; Smith O; De Rosa M; Piciocchi A; Lo Coco F; Foà R; Locatelli F; Kaspers GJL
Blood; 2018 Jul; 132(4):405-412. PubMed ID: 29789356
[TBL] [Abstract][Full Text] [Related]
2. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
Sanz MA; Montesinos P; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte MR; Martínez L; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Vellenga E; Holowiecka A; González-Huerta AJ; Fernández P; De la Serna J; Brunet S; De Lisa E; González-Campos J; Ribera JM; Krsnik I; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Rego EM;
Ann Hematol; 2015 Aug; 94(8):1347-56. PubMed ID: 25975975
[TBL] [Abstract][Full Text] [Related]
3. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group.
Ortega JJ; Madero L; Martín G; Verdeguer A; García P; Parody R; Fuster J; Molines A; Novo A; Debén G; Rodríguez A; Conde E; de la Serna J; Allegue MJ; Capote FJ; González JD; Bolufer P; González M; Sanz MA;
J Clin Oncol; 2005 Oct; 23(30):7632-40. PubMed ID: 16234524
[TBL] [Abstract][Full Text] [Related]
4. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
Kutny MA; Alonzo TA; Gerbing RB; Wang YC; Raimondi SC; Hirsch BA; Fu CH; Meshinchi S; Gamis AS; Feusner JH; Gregory JJ
J Clin Oncol; 2017 Sep; 35(26):3021-3029. PubMed ID: 28767288
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
Kutny MA; Alonzo TA; Abla O; Rajpurkar M; Gerbing RB; Wang YC; Hirsch BA; Raimondi S; Kahwash S; Hardy KK; Hardy S; Meshinchi S; Gamis AS; Kolb EA; Feusner JH; Gregory J
JAMA Oncol; 2022 Jan; 8(1):79-87. PubMed ID: 34762093
[TBL] [Abstract][Full Text] [Related]
6. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract][Full Text] [Related]
7. Outcome for pediatric acute promyelocytic leukemia patients at Children's Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance).
Kutny MA; Geyer S; Laumann KM; Gregory J; Willman CL; Stock W; Larson RA; Powell BL; Feusner JH
Pediatr Blood Cancer; 2019 Mar; 66(3):e27542. PubMed ID: 30393935
[TBL] [Abstract][Full Text] [Related]
8. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group.
Lo-Coco F; Avvisati G; Vignetti M; Breccia M; Gallo E; Rambaldi A; Paoloni F; Fioritoni G; Ferrara F; Specchia G; Cimino G; Diverio D; Borlenghi E; Martinelli G; Di Raimondo F; Di Bona E; Fazi P; Peta A; Bosi A; Carella AM; Fabbiano F; Pogliani EM; Petti MC; Amadori S; Mandelli F;
Blood; 2010 Oct; 116(17):3171-9. PubMed ID: 20644121
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.
Adès L; Thomas X; Bresler AG; Raffoux E; Spertini O; Vey N; Marchand T; Récher C; Pigneux A; Girault S; Deconinck E; Gardin C; Tournilhac O; Lambert JF; Chevallier P; de Botton S; Lejeune J; Dombret H; Chevret S; Fenaux P
Haematologica; 2018 Dec; 103(12):2033-2039. PubMed ID: 30026341
[TBL] [Abstract][Full Text] [Related]
10. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group.
Sanz MA; Martín G; González M; León A; Rayón C; Rivas C; Colomer D; Amutio E; Capote FJ; Milone GA; De La Serna J; Román J; Barragán E; Bergua J; Escoda L; Parody R; Negri S; Calasanz MJ; Bolufer P;
Blood; 2004 Feb; 103(4):1237-43. PubMed ID: 14576047
[TBL] [Abstract][Full Text] [Related]
11. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
12. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
[TBL] [Abstract][Full Text] [Related]
13. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
[TBL] [Abstract][Full Text] [Related]
14. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.
Sanz MA; Martín G; Rayón C; Esteve J; González M; Díaz-Mediavilla J; Bolufer P; Barragán E; Terol MJ; González JD; Colomer D; Chillón C; Rivas C; Gómez T; Ribera JM; Bornstein R; Román J; Calasanz MJ; Arias J; Alvarez C; Ramos F; Debén G
Blood; 1999 Nov; 94(9):3015-21. PubMed ID: 10556184
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of data from 73 patients with childhood acute promyelocytic leukaemia receiving modified chemotherapy: a single-centre study.
Zhang ZX; Lu AD; Wu J; Zuo YX; Jia YP; Zhang LP; Qin J
J Cancer Res Clin Oncol; 2021 Apr; 147(4):1189-1201. PubMed ID: 33006673
[TBL] [Abstract][Full Text] [Related]
16. All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status.
Xu LW; Su YZ; Tao HF
Curr Med Sci; 2021 Jun; 41(3):491-497. PubMed ID: 34169421
[TBL] [Abstract][Full Text] [Related]
17. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Woods WG; Ogden A; Weinstein H; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
Blood; 2002 Dec; 100(13):4298-302. PubMed ID: 12393590
[TBL] [Abstract][Full Text] [Related]
18. Role of cytarabine in paediatric acute promyelocytic leukemia treated with the combination of all-trans retinoic acid and arsenic trioxide: a randomized controlled trial.
Zhang L; Zou Y; Chen Y; Guo Y; Yang W; Chen X; Wang S; Liu X; Ruan M; Zhang J; Liu T; Liu F; Qi B; An W; Ren Y; Chang L; Zhu X
BMC Cancer; 2018 Apr; 18(1):374. PubMed ID: 29615003
[TBL] [Abstract][Full Text] [Related]
19. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.
Gore SD; Gojo I; Sekeres MA; Morris L; Devetten M; Jamieson K; Redner RL; Arceci R; Owoeye I; Dauses T; Schachter-Tokarz E; Gallagher RE
J Clin Oncol; 2010 Feb; 28(6):1047-53. PubMed ID: 20085935
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.
Fenaux P; Chastang C; Chevret S; Sanz M; Dombret H; Archimbaud E; Fey M; Rayon C; Huguet F; Sotto JJ; Gardin C; Makhoul PC; Travade P; Solary E; Fegueux N; Bordessoule D; Miguel JS; Link H; Desablens B; Stamatoullas A; Deconinck E; Maloisel F; Castaigne S; Preudhomme C; Degos L
Blood; 1999 Aug; 94(4):1192-200. PubMed ID: 10438706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
